What Generate:Biomedicines does
Generate:Biomedicines (Nasdaq: GENB) is a clinical-stage therapeutics company focused on “generative biology”: a protein-design and development engine intended to let the company create protein-based drug candidates with defined biological intent. The company’s operating thesis is that programmable generation (as opposed to mainly screening/searching through existing protein space) can reduce time and uncertainty in protein therapeutic development by coupling machine-learning-driven design with iterative experimentation. Generate’s platform is described as The Generate Platform / Generate Platform, a continuous loop that generates, builds, measures, and learns, and that is designed to be therapeutic-area and protein-modality agnostic across multiple modalities (e.g., antibodies and other protein modalities) while producing proprietary data used to improve the system over time. The company’s publicly described pipeline includes clinical and preclinical programs built from this platform, with named clinical candidates such as GB-0895 (anti-TSLP; severe asthma), GB-0669 (SARS-CoV-2; first-in-human program described by the company), and a CAR-T program developed in collaboration with Roswell Park (GB-5267; MUC16-directed armored CAR T). Generate also publicized partnerships and co-development agreements with large biopharma and research institutions (including Amgen and collaborations with cancer centers such as Roswell Park). As of 2026-09-11, Generate is operating as a public company and reporting regularly via quarterly financial news releases and SEC filings.